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Ligand discovery and virtual screening using the
program LIDAEUS
P Taylor, E Blackburn, YG Sheng, S Harding, K-Y Hsin, D Kan, S Shave and MD Walkinshaw
The Centre for Translational and Chemical Biology, The University of Edinburgh, Michael Swann Building, King’s Buildings, Mayfield
Road, Edinburgh, UK
This paper discusses advances in docking and scoring approaches with examples from the high-throughput virtual screening
program LIDAEUS. We describe the discovery of small molecule inhibitors for the immunophilin CypA, the cyclin-dependent
kinase CDK2 and the cyclapolin series of potent Polo-like kinase inhibitors. These results are discussed in the context of
advances in massively parallel computing and in the development of annotated databases.
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Abbreviations: CDK, cyclin-dependent kinase; CypA, human cyclophilin-A; CLogP, the octanol-water partition coefficient,
calculated using the Biobyte program (http://biobyte.com.index.html) developed by Hansch and Leo;
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Virtual screening overview: tools and
approaches
Ligand discovery can be regarded as a simple matching
problem: we would like to find a small molecule (ligand)
with the appropriate shape and charge properties to bind
effectively to a target protein of interest. High-throughput
screening (HTS) provides one possible experimental route to
a solution and libraries consisting of over 1 million
compounds can be tested in days. Computational screening
provides a complementary approach and with massively
parallel processing, millions of compounds per week can be
tested. Estimates of the number of potential small molecule
drug-like compounds vary between 1018 and beyond 1063
(Lipinski and Hopkins, 2004). Consequently, for any specific
target protein, even if the results from each assay and
each docking run were totally reliable (which is not the
case), it would still be impossible to test binding for every
potential ligand. The commonly accepted Lipinski criteria
(Lipinski et al., 1997) for orally active drug-like molecules
set physicochemical property limits to increase the prob-
ability of good drug bioavailability. Drug-like molecules are
expected to have a molecular weight (MW) p500 Da, p5
hydrogen bond donors (HBDs), p10 hydrogen bond accep-
tors (HBAs) and a CLog P p5 (the octanol-water partition
coefficient calculated as described by Moriguchi et al. (1992)
(MLogP)p4.15). More stringent criteria have been proposed
for initial searches. For example, Lead likeness restricts MW
to o350 Da and CLogP (the octanol-water partition coeffi-
cient, calculated using the Biobyte program (http://biobyte.
com.index.html) developed by Hansch and Leo) to o3
(Teague et al., 1999). Even these more stringent cutoffs do
little to reduce the astronomical numbers of potential
ligands and exploring such a large-scale-matching problem
will require imaginative computational and experimental
approaches.
Protein targets
Recent reviews have attempted to estimate the number of
druggable proteins in the Protein Data Bank (PDB) (Berman
et al., 2000). Druggable proteins have structural features that
facilitate binding to drug-like molecules. For proteins to
progress from intrinsic druggability to becoming a target
requires drug binding to modulate the biological role of the
protein and to bring about therapeutic benefit (Fishman and
Porter, 2005). Currently available literature identifies 1300
studied protein drug targets from humans and infective
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organisms (Hopkins and Groom, 2002; Russ and Lampel,
2005; Zheng et al., 2006). Estimates of the total number of
druggable targets in the human genome have been made
based on the number of disease genes; these give a total of up
to 1500 targets out of 25 000 in the human genome (Hopkins
and Groom, 2002). Bacterial and viral proteins also provide
targets; published estimates of the number of targets from
infective organisms are well over 1000. This suggests that
there should be a pool of about 3000 drug targets in total
(Zheng et al., 2006).
Of the 1300 currently studied targets, 44% are classified as
enzymes, the most populated biochemical class. A total of
557 enzymes are current research targets and 134 have
proved to be successful targets. Enzymes represent 50% of all
successful targets (Zheng et al., 2006). A total of 280 research
targets have experimentally determined structures with a
specific drug-binding domain (represented by 107-folds),
mainly by X-ray crystallography.
Within the PDB, there are about 250 uniquely different
(that is o10% amino acid identity) well-determined struc-
tures in complex with ‘peptide-ligands’. These represent a
subset of protein–protein interactions where the interaction
is controlled by a linear peptide on one side of the interface.
Table 1 shows some examples of protein–peptide inter-
actions. This group possibly represents the most druggable
subset of protein–protein interactions. Short linear peptides
are more amenable to replacement by small molecule
mimetics. Modulating protein–protein interactions is parti-
cularly attractive due to the pivotal role of such interactions
in cell signal transduction pathways and cell cycle progres-
sion (Fry and Vassilev, 2005; Chene, 2006).
There are a number of publicly accessible sources of
protein–ligand binding affinities and web-based tools de-
signed to aid the extraction of information from databases
containing structural information on protein targets. For
example, the BindingDB is a public, web-accessible database
of measured binding affinities for biomolecules and contains
data generated by isothermal titration calorimetry and
enzyme inhibition (http://www.bindingdb.org/). The Reli-
base database (http://relibase.ebi.ac.uk/) is a web-based tool
for the study of protein–ligand interaction. MSDmotif
(http://www.ebi.ac.uk/msd-srv/msdmotif/) provides a tool
for summarizing structural information on a database of
over 6000 protein–ligand complexes found in the PDB.
Small molecule databases
A number of publicly available small molecule databases
have been established over the last few years. The ligand.Info
database (http://ligand.info) (Grotthuss et al., 2004) is a
compilation of a number of publicly available databases
providing a Meta-Database of over 1 million entries with
calculated three-dimensional (3D) structures and some
information about biological activity. The ZINC database
(http://blaster.docking.org/zinc/) contains over 4.6 million
commercially available compounds in various 2D and 3D
formats (Irwin and Shoichet, 2005). Only compounds with
MW p700 Da, and calculated LogP values between –4 and 6
are stored. Simple Lipinski filters or other discreet subsets of
compounds can be selected.
An ambitious project financed by the National Institutes
of Health has the goal of discovering sets of molecules that
will specifically modulate the activities of the majority of
gene product in the human and other organisms. Fast
expanding databases are now being developed that
contain results from a number of high-throughput screens,
many of which use a set of over 100 000 chemically diverse
molecules. These data are available at NCBI’s database of
small organic molecules at http://www.ncbi.nlm.nih.gov/
sites/entrez?db¼pcassay.
EDULISS, the EDinburgh University Ligand Selection
System, is our in-house relational database that stores over
5 million available compounds, containing data from over
25 chemical catalogues. Of the 5.3 million compounds, 3.8
million are unique. 3D coordinates for each molecule are
stored with over 1500 topological, geometric, physicochem-
ical and toxicological descriptors per compound (Todeschini
and Consonni, 2005). The descriptors can be used inter-
actively to select subgroups of the database and also to
provide profiling information. One approach to identify
unique compounds is to compare the chemical graph of each
compound with the graph of every other. This approach is
extremely computationally expensive. An alternative meth-
od for identifying unique compounds in EDULISS’s large
collection has been developed. A small number of descrip-
tors including a 3D-Wiener index, an electronegativity
descriptor and a polarizability descriptor are used to group
compounds. The resulting small groups of molecules
with identical descriptors can then be compared using a
Table 1 Examples of protein-peptide interactions in the Protein Data Bank
PDB Protein Peptide Peptide sequence Function Reference
1YCR MDM2 p53 SQETFSDLWKLLPEN Antitumour (Vassilev et al., 2004)
1BXL (NMR) Bcl-XL Bak-BH3 GQVQRQLAIIGDDINR Apoptosis (Degterev et al., 2001)
1EBA EPO EPOR GGTXSCHFGPLTWVCKPQGG Anaemia (Qureshi et al., 1999)
1EJ4, 1WKW EiF4e EiF4e-BP RIIYDRKFLMECRN Malignant transformation (de and Graff, 2004)
1AXC PCNA p21 GRKRRQTSMTDFYHSKRRLIFS Antitumour (Gulbis et al., 1996)
1CKA c-CRK C3G PPPALPPKKR Oncogene (Wu et al., 1995)
1GUX Rb tumour suppressor E7 peptide DLYCYEQLN Antitumour (Lee et al., 1998)
1H9O SH2 Penta -peptide XVPML Signal transduction, cancer (Pauptit et al., 2001)
1QZ2 FKBP52 Hsp90 MEEVD Steroid signalling pathways (Wu et al., 2004)
1ELR HOP Hsp90 XMEEVD Signalling pathways (Scheufler et al., 2000)
1YVH c-CBL APS GRARAVENQXSFY Oncogene (Hu and Hubbard, 2005)
1G3F (NMR) XIAP-Bir3 Smac AVPIAQKSE Apoptosis (Liu et al., 2000)
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graph-matching program. A web-based interface for EDULISS
has been developed; this provides a convenient way of
extracting families of compounds with a user-defined set of
properties.
Database profiling and compound selection
The EDULISS database comprises 25 different commercial
and other smaller specialist compound collections. Of these,
some 4.3 million fit the Lipinski ‘rule of 5s’ (Lipinski et al.,
1997). A total of 3.2 million fit the Oprea lead-like criteria
(Hann and Oprea, 2004). The more stringent Astex Rule of 3
is met by 230 000 compounds (Carr et al., 2005) (statistical
profiles of some general descriptors are shown in Figure 1,
descriptor ranges are shown in Table 2). A study by Oprea
et al. (2007) investigated recent trends in the property space
of leads, drugs and chemical probes. Leads are generally
smaller, less complex and have lower LogP than drugs, due to
the inevitable modifications involved in the medicinal
chemistry optimization process.
It is desirable for a set of compounds for docking or assay
to be selected considering both protein target and screening
methodology. Solubility is of key importance for both
bioavailability and ‘screenability’. Experimentally derived
aqueous solubility data are not available for the majority
of compounds in the EDULISS database. Algorithms for
predicting aqueous solubility from structure almost univer-
sally rely on a directly proportional relationship between
LogP and solubility (Jorgensen and Duffy, 2002; Delaney,
2005). It might be appropriate to have a relaxed solubility
requirement (MLogP p4.21) and to include relatively large
compounds (p450 Da) with the aim of finding leads of high
affinity and high specificity for the target. A greater range of
molecular complexity may be explored with a higher MW
cutoff (Schuffenhauer et al., 2006). However, the application
of X-ray crystallography in lead discovery has different
property requirements. The technique identifies fragments
binding to significant regions of the target protein and then
employs fragment growing or linking strategies to improve
potency. Fragments are small molecules, 100–250 Da, with
few functional groups (Rees et al., 2004; Carr et al., 2005;
Hartshorn et al., 2005). In these techniques, virtual hit
ligands are soaked into crystals. Relative protein concentra-
tions are high, necessitating high ligand concentrations.
Solubility problems can be compounded by the practice of
soaking with a fragment cocktail to increase assay through-
put. Virtual screening subsets designed for fragment screens
Figure 1 Molecular property profiles of 5.3 million compounds in the EDULISS database. (a) MW. (b) MLogP. (c) Number of HBDs. (d)
Number of HBAs. Bin sizes for MWs are 5 Da and for MLogP, the number of HBDs and HBAs 1 U. EDULISS, EDinburgh University LIgand
Selection System; HBA, hydrogen bond acceptor; HBD, hydrogen bond donor; MLogP, the octanol-water partition coefficient calculated as
described by Moriguchi et al. (1992); MW, molecular weight
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need to have stringent solubility requirements, MLogPp3.0,
while containing diverse scaffolds decorated with a broad
range of functional groups (Moriguchi et al., 1992).
High-throughput virtual screening
High-throughput virtual screening achieves a high through-
put of test ligands by using simplified non-quantum
mechanical methods without the inclusion of complex
molecular dynamics (Woo and Roux, 2005). Typically, the
virtual screening process follows the steps outlined in
Figure 2. A ligand is selected and positioned into the target
protein-binding pocket in a given ‘pose’ (Muegge and
Martin, 1999). The resultant complex is scored on the basis
of intermolecular contacts to give a predicted strength of
binding interactions (Woo and Roux, 2005). Flexible docking
typically allows sampling of ligand and sometimes protein
conformations during the docking procedure. Rigid body
docking is however much less computationally expensive.
Exploring the conformers of relatively simple molecules
containing only three or four rotatable bonds (using a broad
step size) requires the generation of over 200 starting
conformations to be sampled in order to fully consider the
majority conformational space (Guner et al., 2004). The most
widely used flexible docking tools are GOLD (Genetic
Optimization for Ligand Docking) (Jones et al., 1997), FlexX
(Rarey et al., 1996; Kramer et al., 1999), DOCK (Ewing et al.,
2001), AutoDock (Goodsell et al., 1996), Glide (Friesner et al.,
2004; Halgren et al., 2004) and ICM (Internal Coordinate
Mechanics) (Abagyan et al., 1994). A variety of different
methods are used by the above tools to deal with ligand
flexibility such as genetic algorithms, incremental construc-
tion, simulated annealing and Monte Carlo methods
(Rosenfeld et al., 1995; Vieth et al., 1998). The diversity
exhibited by scoring functions has been used in consensus
scoring is implemented in, for example, X-SCORE (Wang
et al., 2003). Using different but well-performing scoring
functions, the accuracy of consensus methods can be greater
than any individual scheme (Bissantz et al., 2000; Stahl and
Rarey, 2001; Jacobsson et al., 2003; Raymond et al., 2004;
Xing et al., 2004; Feher, 2006). However, ‘artificial enrich-
ment’ is a potential pitfall, with scoring functions selected to
perform well on a specific protein–ligand complex (Verdonk
et al., 2004).
Perola et al. (2004) have reported that energy minimiza-
tion can significantly improve the accuracy of docking poses
found by GOLD (Jones et al., 1997) and ICM (Abagyan et al.,
1994) programs. Our results also showed that there is better
agreement between the docked pose and the crystallographic
pose using rigid body refinement. A ‘good fit’ is defined as an
root mean square distance (RMSD) p2 A˚ between corre-
sponding heavy atoms of the X-ray structure and the docked
ligand pose.
Virtual screening has proved successful in a number of
projects (Alvarez, 2004; Kitchen et al., 2004; Oprea and
Matter, 2004; Ghosh et al., 2006) (Table 3). One of the major
future challenges is to develop virtual screening methods
capable of identifying ligands that will interrupt protein–
protein interactions.
LIDAEUS as a tool for high-throughput virtual
screening
LIDAEUS, LIgand Discovery at Edinburgh UniverSity, our
in-house high-throughput virtual screening program (Wu
et al., 2003) generates a grid of site points in the binding
pocket of the target protein. Each site point is coloured: HBA,
HBD or hydrophobic, depending on the preferred protein
interaction (Figure 3).
Each molecule selected from the small molecule database
is placed in the binding pocket and atoms of the docked
molecule are matched to site points. An exhaustive fit of a
given number of atoms from the docked molecule onto the
site points is undertaken to identify reasonable poses. These
are stored for subsequent rigid body energy minimization.
Table 2 Descriptor ranges for the EDULISS database of 5.3 million
compounds
Descriptor Max Average Standard deviation
Molecule weight 2180.59 374.28 95.77
Number of bonds 306 47.05 13.05
Number of aromatic bonds 69 13.42 5.97
Number of rings 18 3.14 1.18
Sum of atomic van der Waals
volumesa (A˚3)
172.82 29.29 7.71
Number of rotatable bonds 77 5.31 2.73
MLogP 134.05 3.29 3.35
Topological polar surface areab (A˚2) 932.34 73.66 42.23
Abbreviations: EDULISS; LIgand Discovery at Edinburgh UniverSity; MLogP,
the octanol-water partition coefficient calculated as described by Moriguchi
(Moriguchi et al., 1992).
aScaled on Carbon atom.
bUsing N, O, S, P polar contributions (Todeschini and Consonni, 2005).
Docking 
LIDAEUS 
Post-Processing 
e.g. Cluster analysis, pose analysis
Selection of Compounds for Assay
Protein Target Database 
EDULISS 
5.3 million 
compounds
Scoring
Figure 2 Steps involved in virtual screening using LIDAEUS.
LIDAEUS, LIgand Discovery at Edinburgh UniverSity.
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Table 3 Examples of hits from virtual screening experiments
Target Virtual screening Example structure* Reference Assay
Carbonic
anhydrase II
FlexX (Rarey et al., 1996)
N
N
S
O
O
NH2
(Gruneberg et al., 2002) IC50 Sub
nanomolar
Bcl-2 DOCK (Ewing et al., 2001)
Br
O NH2
O
O
N
O
O
(Wang et al., 2000; Enyedy et al.,
2001)
IC50 9 mM
CK2 DOCK (Ewing et al., 2001) *
NH
N
OH
O
O
(Vangrevelinghe et al., 2003) IC50 80 nM
Plk1 LIDAEUS (Wu et al., 2003)
SCF3
NO2
N
+
S NH2
O
O
(McInnes et al., 2006) IC50 20 nM
GPCR Five targets 5-HT1A, 5-HT4,
Dopamine
D2, NK1, and CCR3
Compound PRX-93009 scored best for
5-HT1A, no structure shown
(Becker et al., 2004) Ki 1.0 nM
Integrin a4b1 Catalyst (Greene et al., 1994) *
CH3
N
H
N
H
N
H
CH3
O
OH
O
O
(Singh et al., 2002) IC50 1.3 nM
ERb GOLD 2.0 (Jones et al., 1997)
OH O
OH
(Zhao and Brinton, 2005) IC50 0.68 mM
TGT Unity/FlexX (Rarey et al., 1996)
N
N
N
NH
O
NH2
(Brenk et al., 2003) IC50 0.25 mM
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There are various tunable parameters that influence how
thoroughly the binding pocket is explored and hence the
time required to dock a series of compounds. The precision
with which an atom matches the site point, called ‘resolu-
tion’ in this program, is usually set between 0.02 and 0.06 A˚
and plays an important role in determining the number of
allowed starting poses. Resolution values greater than 0.06 A˚
lead to an exponential growth in the number of starting
poses. Increasing the number and density of the site points
has a similar effect of dramatically increasing the number of
allowed starting poses.
In LIDAEUS, there are two built-in scoring functions, a
force field-based energy function and pose interaction profile
(PIP) a knowledge-based function (Kan, 2007). The energy
function is essentially a linear combination of van der Waals
and hydrogen bonding energies. The geometry-dependent
hydrogen bonding term incorporates salt bridges and
obviates the need for calculating hydrogen atom positions.
The program assigns fixed formal charges to identify
ionizable groups.
The PIP score uses a protein interaction profile that can be
assigned for specific regions of the binding pocket where
explicit types of ligand interactions, for example, a particular
hydrogen bond, are required. The PIP string is a hexadecimal
code containing information about the interactions made
between a given set of protein residues and the docked
ligand. The target PIP string is usually based on a known
X-ray crystal structure in which key features of the protein–
ligand binding interaction have been identified. It is a very
efficient process to match and score the bit strings of the
target interactions against those calculated for the docked
ligand pose. Thus, the PIP score can be used as a component
of the final score to ensure that docked ligands have both
favourable energies of interaction and satisfy specific inter-
actions in their pose.
While LIDAEUS is broadly similar in function to many
docking programs, it differs in two major areas: the extent to
which the fitting protocol can be modified by the user and
the modularity of the system. All definitions within the
program in the way of atom and site point types are soft, that
is, can be customized by the user. This happens at two levels:
one can initially type individual atoms according to
connectivity criteria and then group many or one of these
types into colours used in the pose generation or scoring
process. While using the default definitions allows for
standard searches using atoms grouped into broad classes
such as hydrophobic, HBA and HBD, it is possible to add
specific restrictions.
LIDAEUS exists as a series of modules that run as a UNIX
pipeline, so that initial typing of molecules, posing, scoring
and sorting are all separate programs. It allows us to easily
develop experimental modules and test different scoring
methods. The program is being developed in two areas. The
current flexible docking module is too slow to be used in a
high-throughput mode and this is being addressed. Sec-
ondly, a front end is being written that allows intermediate
users the ability to easily configure customizable features.
Table 3 Continued
Target Virtual screening Example structure* Reference Assay
CDK2 LIDAEUS (Wu et al., 2003)
N
N
S
N
N
N
OH
(Wu et al., 2003) IC50 2.2 mM
Structures marked with an asterisk do not represent those initially identified by in silico screening. Minor chemical modifications have been made and from these
compounds the experimental data determined.
Figure 3 LIDAEUS site points in the binding pocket of CypA in
complex with cyclosporine-A (PDB code 1cwa). Each site point is
coloured depending on the preferred protein interaction (HBA, red;
HBD, blue; hydrophobic, grey). The magenta sphere represents a
key water molecule. Key residues are shown in bold. CypA, human
cyclophilin-A; HBA, hydrogen bond acceptor; HBD, hydrogen bond
donor; LIDAEUS, LIgand Discovery at Edinburgh UniverSity; PDB,
Protein Data Bank.
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The examples discussed in the paper were run on a modest
seven-node cluster. Run times are dependent on the target
protein, the ligand complexity and the site point resolution
set for LIDAEUS. However, representative times for a
database of 50 000 ligands would be 6 h. Using an IBM Blue
Gene/L supercomputer, run times have been reduced from 8
days on a seven-node cluster to 62 min on 1024 processors
using a standard data set of 1.67 million small molecules.
Validation of LIDAEUS docking and scoring
performance
The immunophilin proteins FKBP (FK506 Binding Protein)
and human cyclophilin-A (CypA) have been used as test
systems to develop and test the results from the database
mining program LIDAEUS. Despite having similar biological
profiles, the structure and active site of the two proteins are
very different. Both proteins have peptidyl-prolyl isomerase
activity and speed up the cis–trans equilibration of proline
residues by lowering the barrier to rotation about the imide
bond (Fischer et al., 1993). Inhibition of the enzymatic
turnover of an immunophilin substrate provides a functional
assay for screening potential inhibitors (Fischer et al., 1984).
X-ray crystallographic, surface plasmon resonance, iso-
thermal titration calorimetry and mass spectrometry results
provide complementary techniques for characterizing ligand
binding.
A set of nine chemically related ligands of human CypA
with IC50 values between 2 and 100mM were used to test
LIDAEUS docking performance (referred to as the test set).
For each ligand, the X-ray structure is known and the RMSD
between corresponding atoms of the X-ray structure and the
ligand structure is used as a measure of fit. Correct docking
poses (RMSDp2 A˚) of ligand 1 in the test set (Figure 4 shows
the correlation of PIP score and energy score were E, with
RMSD from X-ray structure for a ligand in the test set) were
all scored 40.93 by the PIP function and their energy scores,
Eo11 kcal mol1. PIP scores are normalized between 0 and
1: a high PIP score indicates conserved interactions between
those in the X-ray structure and the docked pose. The other
ligands in the CypA test set have similar results, showing
that a combined total score of energy function and PIP
(matching a defined pose iinteraction profile) ranks the
correct docking binding mode higher than alternative poses
(Equation 1).
S ¼ W1Eþ W2
X
i
PIPi ð1Þ
S, total score; E, force field-based energy score; PIP, knowl-
edge-based PIP score; W1, weighting factor specific to protein
system; W2, weighting factor specific to protein system.
For a set of nine related cyclophilin inhibitors, the effect of
changing the weights W1 and W2 was examined by system-
atically trialling different values. For this series of com-
pounds, the values that gave the best RMSD fit of the docked
pose compared to the crystallographic pose were weights of 1
and 40 for W1 and W2, respectively. These values proved
useful in identifying a new series of cyclophilin ligands (Kan,
2007).
The role of water in accurate docking
It has been reported in several studies that water-mediated
protein–ligand interactions are an important factor in the
docking process. Ligands can displace water in the active site
or incorporate them as an extension of the protein surface.
The presence of key water molecules can significantly
improve docking performance (Pospisil et al., 2002; Yang
and Chen, 2004). Our results show that eight out of nine
ligands in the test set were correctly docked into near-native
positions by LIDAEUS, while re-docking of six of them was
significantly improved when key water molecules were
included in the protein–ligand binding system. The presence
of the key waters enables the LIDAEUS program to identify
several important interactions involved in the complex and
construct the significant HBA or HBD site points at the
binding atom locations. (Key waters are those that form
bridging H bonds to both protein and ligand molecules).
Ligand 7 (Figure 5) is an example where including water
improved docking performance. The presence of the key
waters enables the LIDAEUS program to construct the
significant HBA or HBD site points at the binding atom
Figure 4 Correlation of PIP score and energy score, E, with RMSD from X-ray structure for ligand 1 of the CypA test set. (a) Plot of PIP score
against RMSD of docking poses with respect to X-ray structure. (b) Plot of energy score, E, against RMSD with respect to X-ray structure. Red
boxes highlight ‘good poses’ that meet scoring cutoffs: PIP score40.93, energy scoreo11 kcal mol1. CypA, human cyclophilin-A; PIP, pose
interaction profile; RMSD, root mean square distance.
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locations. Furthermore, energy maps contoured with the
presence of key waters better represent the energy distribu-
tion in the local area. Thus, those maps would give the
correct fits lower energy scores than maps generated without
key waters.
Discovery of ligands for immunophilins
In a test to find CypA ligands, the ZINC database (Irwin and
Shoichet, 2005) of 2 million compounds was used as an
input for a LIDAEUS screen looking for compounds that
would match site points in the active site of CypA (two
parallel runs using 60 site points with a resolution of 0.06 A˚
and 170 site points with a resolution of 0.04 A˚). The top 2000
poses were re-ranked, specifying that hydrophobic inter-
actions with Phe113 and a hydrogen bond to Arg55 were
satisfied, using PIP scoring (Figure 6).
The combined energy and PIP scores ranged from 164 to
80 (arbitrary units). The top 360 unique compounds were
grouped according to chemical similarity (using molecular
fingerprinting and Tanimoto coefficients) and binding mode
(visually using Pymol). From this analysis, 14 compounds
(all chemically distinct from known cyclophilin inhibitors)
were purchased and tested for inhibition and binding by
peptidyl-prolyl isomerase assay (Kofron et al., 1991). Eleven
compounds showed a statistically significant reduction in
peptidyl-prolyl isomerase activity. Six of the 14 compounds
were ‘hits’ in the peptidyl-prolyl isomerase enzymatic assay;
they inhibited CypA with IC50 values ranging from 27 to
135 mM. Subsequent isothermal titration calorimetry studies
for the best three compounds gave Kd values of 2 to 8mM.
Virtual screening for CDK inhibitors using LIDAEUS
Cyclin-dependent kinases (CDKs) are key regulators in all
steps of the cell cycle and as such are interesting targets for
anticancer therapies. There are already a number of clinical
trials underway with CDK2 and CDK4 inhibitors for a range
of cancers (Collins and Garrett, 2005). The small molecule
inhibitors, roscovotine (Seliciclib) and flavopiridol, are
CDK2 inhibitors and show promising activity in lung cancer.
These drugs target the ATP binding site of the CDKs. This is a
problem in the design of CDK selective drugs, as all nine
CDKs show some homology and most of the active site
residues are well conserved. Another complicating factor in
the design of specific inhibitors is that the active form of the
kinase is induced by complex formation with a partner
cyclin and phosphorylation of a specific threonine residue
located on the T-loop of the kinase. These events cause subtle
changes in active site geometry, which may be important for
inhibitor design.
We used LIDAEUS to carry out a virtual screen of 50 000
commercially available compounds from the Maybridge
catalogue (www.maybridge.com) docked into the active site
of CDK2 (taken from the X-ray structure of the CDK2–
staurosporine complex; PDB code 1AQ1). The predicted top
120 poses based on the docking score were screened at a
fixed concentration of 30 mM using an assay to monitor the
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Figure 5 Including water in site point generation. Poses were improved when an essential water molecule was used in the calculation of
energy maps and in site point construction. X-ray structure of the ligand is shown in white and docked poses in pink. (a) Illustrates how one
oxygen atom (O1) from the ligand was put into the experimental position (position A), but the other oxygen atom (O2) was put into position B
instead of position C, as revealed from the X-ray structure. (b) When the important water molecule (in magenta) is included in site point
generation, competent site points set helped bring the oxygen atom to position C.
CypA
Phe113
Arg55
Figure 6 PIP used in the CypA virtual screening experiment. The
top 2000 poses (rank ordered using the energy score, E,) were re-
ranked, specifying that there were predicted hydrophobic interac-
tions with Phe113 (grey lines) and a predicted hydrogen bond to
Arg55 (black dotted lines) using PIP scoring. The diagram shows a
molecule making interactions specified in the PIP. The green dashed
lines are non-covalent interactions not specified in the PIP. CypA,
human cyclophilin-A; PIP, pose interaction profile;
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inhibition of phosphorylation by CDK2/cyclinE. Twenty-
nine percent of the compounds were classed as active by
showing more than 30% inhibition. The most active four
compounds all had a heteroaryl-2-amino-pyrimidine core
and measured IC50 values between 0.9 and 17 mM (Table 4).
X-ray crystal structures of the four hits were obtained and
each was clearly identified in the ATP binding site. A
comparison was made of the calculated docked pose (with-
out any PIP influence) against the experimentally deter-
mined ligand structures. The four ligands were all found to
dock in twisted conformations with a twist of 35o around the
bond between the two aromatic rings. The RMSD atom
against atom fit of the three top scoring docked ligands
versus the experimental structure were 1.6, 1.58 and 3.42 A˚
with scores of 24, 23 and 20 kcal mol1, respectively.
Despite the chemical similarity of these four ligands, they
adopt different binding modes (Table 4) CYC1 and CYC2
form identical hydrogen-bond interactions to ATP: NHy.O
(Glu81), Ny.HN(Leu83) and CHy.O(Leu83). When the
amine group is substituted as in CYC3 and CYC4, the ATP
binding mode is precluded and the ligand flips over to allow
the bulky substituent to point out of the pocket. An
alternative hydrogen bonding pattern is made CHyO
(Glu81), Ny.HN(Leu83) and NHy.O(Leu83). These four
structures provided an excellent starting point for the design
of chemical modifications. Over 40 related structures have
been synthesized to optimize in vivo potency. The tightest
binding ligand of this series, an amino derivative (CYC5),
has a Ki¼2 nM and was shown to induce cell death in
cultured HeLa cells (Wang et al., 2004a, b)
The importance of fine tuning a template structure
in virtual screening
The shape and surface of the target pocket is clearly one of
the most important factors in successful virtual screening
runs. The search for CDK2-specific inhibitors highlighted the
importance of understanding the biological role of the target
protein. A crystallographic study was used to analyse the
structures of six inhibitor ligands belonging to the thiazole-
pyrimidine class, identified by LIDAEUS; both in complex
with monomeric CDK2 and also with the binary CDK2/
cyclinA active complex (Wu et al., 2003; Kontopidis et al.,
2006). The activation of CDK2 by phosphorylation and
cyclin binding causes significant loop and helix movements
but leaves the shape of the ATP binding site relatively
unchanged with a maximum side-chain movement between
1 and 2 A˚ for residues comprising this pocket. However, these
small differences in pocket shape play a major role in the
relative binding strengths of inhibitors. In some cases, the
same ligands can adopt significantly different poses in
the monomeric and active complexes. Binding enthalpies
of the ligands have been estimated based on calculated van
der Waals and hydrogen bond contacts measured in the
crystal. The measured IC50 values correlate well with the
calculated interaction energy (energy score) for the binary
complex, but show poor correlation with the inactive
complex. This fits with the way the assay has been carried
out—using the active complex. It also suggests that the
enthalpic energy-scoring scheme, using van der Waals and
hydrogen bonding terms, provides a self-consistent measure
of binding strength (Kontopidis et al., 2006).
The discovery of cyclapolin, a potent Polo-like
kinase inhibitor
Polo-like kinase 1 (Plk1) controls the G2/M transition of the
cell cycle by phosphorylating a number of substrates that
function in mitotic progression. Overexpression of Plk1 is
frequently observed in tumours and in downregulation,
using small interfering RNA, has been shown to inhibit
cancer cell proliferation (McInnes et al., 2005). Small
molecule Plk-specific inhibitors are valuable biological tools
and can be used as leads for antitumour agents. A number of
general kinase inhibitors, such as staurosporine and purva-
lanol, are known to inhibit Plk1 (McInnes et al., 2005). After
years of intensive effort by academic and pharmaceutical
research groups, the X-ray structure of the kinase domain has
recently been published (Kothe et al., 2007) in complex with
a pyrazole inhibitor (PHA-680626), which has an IC50 value
of 0.5mM (PDB code 2owb). Before this structure became
available, we had developed a homology model of the kinase
domain of Plk based on the staurosporine-bound conforma-
tion of protein kinase A, which has a 31% sequence identity
(PDB code 1stc). The model was shown to be consistent with
the known structure-activity properties of a series of ligands
which were docked into the binding pocket in a similar
manner to that found in CDK2. LIDAEUS was used to dock a
library of 200 000 commercially available compounds into
the modelled active site of Plk1. A total of 350 of the top-
ranked compounds were then assayed by measuring inhibi-
tion of Plk1 phosphorylation of Cdc25C. A number of Plk1
inhibitors were identified with potencies ranging between
0.5 and 20 mM. A series of compounds (named the cyclapo-
lins) based on the benziathole N-oxide core of the most
active hit were synthesized and provide a consistent
structure-activity relationships for the inhibition of Plk1
(Figure 7). The most active compound in this series showed
significant improvement in potency and has an IC50 value of
2 nM. For this series, there is a good correlation between the
docking score and potency. Treatment of HeLa cells with
cyclapolin1 leads to mitotic cells that show severe spindle
abnormalities (McInnes et al., 2006).
Outlook
The evolution of structure-based lead discovery has been
guided by fashion and by some interesting technological
advances. Twenty-five years ago, we had the first useful
molecular graphics systems that could help medicinal
chemists visualize molecular properties. This technology
along with fast data collection and structure determination
of protein X-ray structures opened the path to structure-
based methods. Ironically, in the mid 1990s, just as this
approach was beginning to bear fruit, the fashion swung to
robotics and high-throughput screening, possibly spurred by
the newly founded discipline of Combinatorial Chemistry,
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which made it possible to generate very large libraries of
compounds. Now in larger organizations high-throughput
screening, in silico and structure-based approaches are quite
well integrated.
The main challenges in docking are still the old problems
of how to efficiently model effects including dielectrics,
entropy, water and flexibility. Advances in computer archi-
tectures may help tackle such problems. However, we also
need to design methods that allow efficient simulation of
these effects. Possibilities include using cliques of side
chain conformations around the active site, and hybrid
molecular modelling/quantum mechanical calculations.
High-throughput virtual screening, using simplified meth-
ods (non-quantum mechanical or complex molecular
dynamics), can already achieve docking rates of over 1 M
compounds an hour (Shave et al., 2008).
Table 4 CDK2 inhibitors discovered using LIDAEUS
Compound Kinase inhibition (CDK2/
cyclin E) IC50 (mM)
Hydrogen-bonding pattern Reference
CYC1
N
N N
H
H
S
Cl
Cl
H
17 ATP hydrogen-bonding pattern:
NHy.O(Glu81), 2.96 A˚, Ny.HN(Leu83),
3.64 A˚, CHy.O(Leu83), 3.36 A˚
(Wu et al., 2003)
CYC2
N
N N
H
H
H
N
S
13 ATP hydrogen-bonding pattern:
NHy.O(Glu81), 2.86 A˚, Ny.HN(Leu83),
3.30 A˚, CHy.O(Leu83), 3.25 A˚
(Wu et al., 2003)
CYC3
N
NN
H
HN
OH
N
S
2.2 Alternative hydrogen bonding pattern:
CHy.O(Glu81), 3.31 A˚,
Ny.HN(Leu83),2.82 A˚, NHy.O(Leu83),
2.54 A˚
Ligand flips over to allow the bulky
substituent to point out of the pocket
(Wu et al., 2003)
CYC4
N
N
N
S
HN
H
CF3
0.9 Alternative hydrogen bonding pattern:
CHy.O(Glu81), 3.31 A˚, Ny.HN(Leu83),
2.92 A˚, NHy.O(Leu83), 2.58 A˚
Ligand flips over to allow the bulky
substituent to point out of the pocket
(Wu et al., 2003)
Colour coding denotes atoms involved in key hydrogen-bonding interactions.
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Technical advances in miniaturization (396-well plates)
and sensitive ligand-binding assays are already generating
very large amounts of binding data, which contribute to
structure-activity relationships. Accurate protein–ligand
binding data can add to our understanding of how proteins
recognize ligands. Identifying the key features of successful
virtual screening calculations can only enhance the chances
of discovering new ligands.
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